Halozyme Therapeutics (HALO) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a hold rating to a buy rating in a report issued on Tuesday.

HALO has been the subject of a number of other research reports. Zacks Investment Research cut Halozyme Therapeutics from a buy rating to a hold rating in a research report on Thursday, August 24th. Deutsche Bank upped their target price on Halozyme Therapeutics to $20.00 and gave the stock a buy rating in a research report on Friday, September 15th. Canaccord Genuity upped their target price on Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a buy rating in a research report on Wednesday, November 8th. BMO Capital Markets upped their target price on Halozyme Therapeutics from $14.00 to $15.00 and gave the stock a market perform rating in a research report on Friday, September 15th. Finally, Barclays cut Halozyme Therapeutics from an overweight rating to a hold rating and upped their target price for the stock from $16.00 to $19.00 in a research report on Wednesday, November 22nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $18.50.

Shares of Halozyme Therapeutics (NASDAQ HALO) opened at $19.57 on Tuesday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.37. Halozyme Therapeutics has a 12-month low of $9.68 and a 12-month high of $19.94.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The company had revenue of $63.73 million for the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The firm’s revenue for the quarter was up 100.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.23) EPS. equities analysts predict that Halozyme Therapeutics will post 0.27 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. IFP Advisors Inc boosted its position in shares of Halozyme Therapeutics by 1.6% in the second quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock valued at $188,000 after acquiring an additional 226 shares during the period. ProShare Advisors LLC boosted its position in shares of Halozyme Therapeutics by 0.5% in the second quarter. ProShare Advisors LLC now owns 82,187 shares of the biopharmaceutical company’s stock valued at $1,054,000 after acquiring an additional 374 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Halozyme Therapeutics by 0.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 57,963 shares of the biopharmaceutical company’s stock valued at $742,000 after acquiring an additional 396 shares during the period. Amalgamated Bank boosted its position in shares of Halozyme Therapeutics by 5.3% in the second quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 705 shares during the period. Finally, Prudential Financial Inc. boosted its position in shares of Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 940 shares during the period. 84.50% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/13/halozyme-therapeutics-halo-upgraded-to-buy-at-bidaskclub.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply